Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 273

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 273
---
 of our compensation committee is independent under the listing standards of Nasdaq and qualifies as a “non-employee director”as defined in Rule 16b-3 promulgatedunder the Exchange Act. The primary responsibilities of the compensation committee will include, among other things:

| • |     | reviewing and approving (or, as applicable, recommending to our board of directors) the compensation of our Chief 
 Executive Officer and other executive officers;                                                                   |

| • |     | reviewing and approving the compensation paid to our non-employee 
 directors;                                                        |

| • |     | administering our equity incentive plans and other benefit programs; |

| • |     | reviewing and approving, or making recommendations to our board of directors with respect to, incentive 
 compensation and equity plans;                                                                          |

| • |     | reviewing, adopting, amending, and terminating the terms of any employment agreements, severance arrangements,                               
 bonus plans, deferred compensation plans, change-of-control protections, and any other compensatory arrangements for our executive officers; |

| • |     | reviewing, evaluating, and recommending to our board of directors succession plans for our executive officers; 
 and                                                                                                            |

| • |     | reviewing and establishing general policies relating to compensation and benefits of our employees, including our 
 overall compensation philosophy.                                                                                  |

The compensation committee will operate under a written charter, to be effective immediately prior to the closing of this offering, which satisfies the applicable rules and regulations of the SEC and the listing standards of Nasdaq. 185

Nominating and Corporate Governance Committee Upon completion of this offering, our nominating and corporate governance committee will consist of Rebecca Luse, Ran Nussbaum and Zachary Prensky, with Ms. Luse serving as chair of the nominating and corporate governance committee. Our board of directors has determined that each of Mr. Nussbaum and Ms. Luse is “independent” as defined under the applicable listing standards of Nasdaq and SEC rules and regulations. Mr. Prensky, by virtue of his former position as our former Chief Executive Officer, is not independent under applicable rules and regulations of the SEC and the Nasdaq listing rules. We are relying on the phase-in exemption provided under Rule 10A-3 of the Exchange Act and the Nasdaq listing rules with respect to the composition of our nominating and corporate governance committee. Mr. Prensky will serve on our nominating and corporate governance committee under the phase-in exemption referenced above. In accordance with the phase-in exemption, a majority of